Gavin David Clark
Directeur/Membre du Conseil chez Lamellar Biomedical Ltd.
Profil
Gavin David Clark founded Procela Partners and MGB Biopharma Ltd., where he worked as Director & Chief Business Officer.
Dr. Clark also currently works at Lamellar Biomedical Ltd., as Non-Executive Director.
Dr. Clark also formerly worked at Angel Biotechnology Holdings Plc, as Non-Executive Director from 2008 to 2012, Johnson & Johnson, as Principal, Bayer AG, as Product Manager, Acumen Pharmaceuticals, Inc., as Vice President-Corporate Development, Pintex Pharmaceuticals, Inc., as Principal, Janssen-Cilag Ltd., as Product Manager, RioTech Pharmaceuticals Ltd., as Executive Vice President-Corporate Development, PLIVA dd, as Principal, GlaxoWellcome, as Principal, Physiomics Plc, as Principal, PowderMed Ltd., as Principal, GlycoForm Ltd., as Head-Business Development from 2008 to 2011, Novartis Pharmaceuticals Corp., as Principal, Affimed NV Niederlassung Deutschland, as Vice President-Business Development, NeuroCure Ltd., as Principal, Tibotec Pharmaceuticals, as Vice President-Business Development, Immunovo BV, as Vice President-Business Development, and Netherlands Translational Research Center BV, as Vice President-Business Development.
Dr. Clark received his undergraduate degree from the University of Strathclyde.
Postes actifs de Gavin David Clark
| Sociétés | Poste | Début |
|---|---|---|
Lamellar Biomedical Ltd.
 Lamellar Biomedical Ltd. Pharmaceuticals: MajorHealth Technology Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom. | Directeur/Membre du Conseil | - |
Anciens postes connus de Gavin David Clark
| Sociétés | Poste | Fin |
|---|---|---|
GlycoForm Ltd.
 GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | Corporate Officer/Principal | 31/08/2011 |
| Tibotec Pharmaceuticals | Corporate Officer/Principal | - |
| GlaxoWellcome /Pharmocology Unit/ | Corporate Officer/Principal | - |
Netherlands Translational Research Center BV
 Netherlands Translational Research Center BV Medical/Nursing ServicesHealth Services Netherlands Translational Research Center BV develops small molecule drug leads and preclinical candidates for cancer, autoimmune and Parkinson diseases. Its product NFK GreenScreen plays an important role in immune modulation and neurodegenerative disease. The firm also offers Oncolines, OncolinesProfiler, SynergyFinder, ResidenceTimer and EntropySelect services. The company was founded by Guido J. R. Zaman and Rogier C. Buijsman in June 2011 and is headquartered in Oss, the Netherlands. | Corporate Officer/Principal | - |
MGB Biopharma Ltd.
 MGB Biopharma Ltd. BiotechnologyHealth Technology MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom. | Fondateur | - |
Formation de Gavin David Clark
| University of Strathclyde | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| ACUMEN PHARMACEUTICALS, INC. | Health Technology |
| PHYSIOMICS PLC | Commercial Services |
| BAYER AG | Health Technology |
| Entreprise privées | 17 |
|---|---|
Affimed NV Niederlassung Deutschland
 Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Health Technology |
PowderMed Ltd.
 PowderMed Ltd. Pharmaceuticals: MajorHealth Technology PowderMed Ltd. develops immunotherapeutic products. It focuses on the clinical development and manufacture of therapeutic and prophylactic DNA-based vaccines for viral diseases and cancer. The company has 4 clinical and 3 pre-clinical stage projects. The company was founded February 25, 2004 by Dr. Clive Dix & Dr. Beadle and is headquartered at Oxford, The United Kingdom. | Health Technology |
Angel Biotechnology Holdings Plc
 Angel Biotechnology Holdings Plc BiotechnologyHealth Technology Angel Biotechnology Holdings Plc operated as a contract bio-manufacturing company that offers process development, pre-GMP and cGMP manufacturing services. The company specialized in offering the cGMP manufacture of advanced biologics including stem cells, cell therapies, recombinant proteins, antibodies and viruses for clinical trial use and commercial sale. It also provided development and manufacturing support for production of biologics working from laboratory scale to development of a robust manufacturing process. Angel Biotechnology was founded on December 7, 2000 and was headquartered in Edinburgh, the United Kingdom. | Health Technology |
RioTech Pharmaceuticals Ltd.
 RioTech Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology RioTech Pharmaceuticals Ltd. develops novel therapeutic drugs for hepatitis C virus. The company was founded on Nov 5, 2001 by Graham Foster, Adrian V. S. Hill, Peter Karayiannis, Howard David Thomas and Mark R. Thursz and is headquartered in Horsham, the United Kingdom. | Health Technology |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | Health Technology |
| GlaxoWellcome /Pharmocology Unit/ | Commercial Services |
| Procela Partners | |
Pintex Pharmaceuticals, Inc.
 Pintex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pintex Pharmaceuticals, Inc. used to discover and develop cancer therapeutics. The company used to discover and commercialize new antibiotics focused on drug resistance. Pintex Pharmaceuticals was founded by Walter Gilbert, Kung Ping Lu and Janusz Sowadski in 1999 and was headquartered in Watertown, MA. | Health Technology |
PLIVA dd
 PLIVA dd Pharmaceuticals: MajorHealth Technology PLIVA d.d. is a joint stock company incorporated and domiciled in the Republic of Croatia. The registered office is at Vukovarska 49, Zagreb. The Company is the parent of the PLIVA Group (“the Group”). The Group manufactures and supplies a wide range of pharmaceutical products as its core business. Non-core businesses consist of the manufacture and supply of DDDI products (diagnostics, disinfectants, dialysis, and infusions). | Health Technology |
NeuroCure Ltd.
 NeuroCure Ltd. BiotechnologyHealth Technology NeuroCure Ltd. manufactures drugs to cure psychiatric and central nervous system diseases. It has programs available for out-licensing and its licensing novel use inventions supported by clinical data and with novel formulations. The company was founded by Ted Dinan and Peter Daly in 2003 and is headquartered in Dublin, Ireland. | Health Technology |
MGB Biopharma Ltd.
MGB Biopharma Ltd. BiotechnologyHealth Technology MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom. | Health Technology |
| Tibotec Pharmaceuticals | |
Lamellar Biomedical Ltd.
Lamellar Biomedical Ltd. Pharmaceuticals: MajorHealth Technology Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom. | Health Technology |
Netherlands Translational Research Center BV
Netherlands Translational Research Center BV Medical/Nursing ServicesHealth Services Netherlands Translational Research Center BV develops small molecule drug leads and preclinical candidates for cancer, autoimmune and Parkinson diseases. Its product NFK GreenScreen plays an important role in immune modulation and neurodegenerative disease. The firm also offers Oncolines, OncolinesProfiler, SynergyFinder, ResidenceTimer and EntropySelect services. The company was founded by Guido J. R. Zaman and Rogier C. Buijsman in June 2011 and is headquartered in Oss, the Netherlands. | Health Services |
Immunovo BV
 Immunovo BV BiotechnologyHealth Technology Immunovo BV develops immune therapeutics in the field of oncology. The firm's research focuses on therapeutic vaccines based on synthetic peptide antigens for which the company applies the novel and proprietary techniques in synthetic immunogen development. Its products include Sclerostin, PD1, PEPA10-adj, Gastrine, VEGF, and GnRH. The company was founded in 2009 and is headquartered in ‘s-Hertogenbosch, the Netherlands. | Health Technology |
Janssen-Cilag Ltd.
 Janssen-Cilag Ltd. Pharmaceuticals: MajorHealth Technology Janssen-Cilag Ltd. provides pharmaceutical products and services. It offers medicines that can treat serious health conditions such as schizophrenia, epilepsy, multiple myeloma, and human immunodeficiency virus/acquired immunodeficiency syndrome. The firm's other key areas of activity include pain management, gastroenterology, fungal infections, women’s health, neurology, and anaemia. The company was founded on October 19, 1971 and is headquartered in High Wycombe, the United Kingdom. | Health Technology |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
